natural remedies for hair loss for men
herbal life shake review
herbal plants in philippines
natural remedies for herpes
herbal essences chestnut
herbal remedy for anxiety
perimenopause anxiety natural remedy
alternative medicine for cancer
natural remedies for ear infections
cancer body wasting herbal remedy
price strategy of herbal essences shampoo
bipolar herbal remedies
herbal essences shower gel
herbal meds for dogs
herbal plants pictures
lung inflammation natural remedy
colitis treatment more alternative medicine
ayurvedic herbal remedies
natural cures they don want you know about
natural health products wholesale
arthritis natural treatment
natural remedy for arthritis dogs
herbal remedies for depression anxiety
natural remedy for arthritis
herbal remedies impotence
overactive bladder natural remedies
Translation Elongation


natural herbal remedies rss

Consistent

herbal medications
with its business strategy and as outlined in this , Cardium plans to raise additional
pregnenolone natural remedy
funds through the strategic sale or monetization of its operating units, entering into strategic licensing agreements, and/or other financing transactions. As our product opportunities and businesses are advanced and corresponding valuations established, we intend to consider various corporate development transactions designed to place our product candidates into larger organizations or with partners having existing commercialization, sales and marketing resources, and a need for innovative products.
herbal medications
CXM) today reported highlights and financial results for its fourth quarter
herbal remedies for metabolism
and fiscal year ended , and other important recent developments and outlook for 2009. This announcement does not reflect any change or amendment to the consolidated financial statements as filed. InnerCool is also positioned to benefit from participation in cutting-edge research efforts with the potential to broaden the applicability
fat dogs herbal remedy miracle herb
of patient temperature modulation for advanced therapies. More information about the going concern qualification is contained in Cardium's Annual Report on Form 10-K for the year ended , which is available free of change on Cardium's website at. InnerCool Therapies completed its high-performance endovascular-based cooling system, RapidBlue(TM), and the system was cleared by the FDA in late 2008. The increase in 2008 product revenues was in large part
herbal medicines
a result of an increase in InnerCool sales resulting from the launch of the CoolBlue surface cooling system in late 2007 and the launch of the RapidBlue in late 2008.

Cardium also has two biologic candidates in clinical development. The Company's Phase 2b MATRIX clinical study was initiated in and is principally designed to evaluate the ability of Excellarate to promote rapid closure of previously non-healing diabetic foot ulcers and to gather Consistent with Cardium's business strategy, the

alternative medicine
Company believes that with the Company's completion of the Phase 2b MATRIX study, the Tissue Repair Company will have reached a key valuation
herbal remedies to calm mares
inflection point within Cardium's investment portfolio and in concert with this, Cardium plans to consider potential development and commercialization partnerships for Excellarate with large pharmaceutical companies and companies focused on wound healing. In addition, through Cardium's investment, InnerCool's product portfolio and pipeline of new and innovative future products are supported by a fully-integrated 29,000 square foot cGMP facility with R&D and manufacturing capabilities.

Cardium Therapeutics, Inc. The

natural treatment for depression
Tissue Repair Company (TRC) was also acquired by Cardium in 2006. Total revenue for the year ended was $2,417,000
herbal medicines
compared to $1,587,000 for the previous year, representing a 52% year-over-year increase.

We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. On , the Company submitted a proposed plan outlining how it could establish compliance with the requirements of section 1003(a)(iv) by , and establish compliance with all sections, including section 1003(a)(i), by. Cardium also plans to explore additional clinical opportunities

herbal life
utilizing TRC's Nevil Activated Matrix(TM) (GAM) technology platform. Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably
cayenne pepper herbal supplements gnc
cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's new RapidBlue(TM) System, which recently received FDA clearance, and its CoolBlue(TM) System, please visit. For
natural cures
more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit or view its most recent Annual Report at /flash/pdf/CardiumAR07_Book_FINAL.pdf. Cardium Reports on Recent Highlights, Financial Results
natural healing remedies
and 2009 Outlook SAN DIEGO, / - / -- Cardium Therapeutics (NYSE Amex. Total revenue for fourth quarter 2008 was $559,000 compared to $683,000 for fourth quarter 2007.

For the year ended , Cardium reported net operating losses totaling $24.6 million, or a loss of $(0.55) per share compared to $25.3 million, or $(0.64) per share in 2007. On , the Company reported

natural remedy
closing a credit facility in the amount of $3.5 million, before placement agent fees and other expenses. Research and development costs in 2008 were $12.3 million compared to $13.1 million for fiscal year 2007, and selling, general and administrative expenses were $11.6 million in 2008 compared to $12.1 million in 2007. Generx(R) (alferminogene tadenovec, Ad5FGF-4) is designed to leverage
herbal remedies holly
the body's natural healing processes in response to repeated ischemic stress (insufficient blood flow and myocardial oxygen supply due to coronary heart disease)
herbal remedies
- for potential use in treating ischemic conditions such as recurrent angina. Such transactions could involve the sale, partnering or other monetization of particular product opportunities or businesses. This announcement is made in compliance with Section 610(b) of the Company Guide of the NYSE Amex (formerly the American Stock Exchange), which requires listed companies to make a public announcement of the receipt of an audit opinion that contains a going concern qualification.

Tissue Repair Company successfully advanced its MATRIX Phase 2b clinical study, which is principally

natural cures
designed to evaluate the ability of Excellarate(TM) to promote rapid closure of previously non-healing
trinity college natural health
diabetic foot ulcers, and to gather InnerCool was acquired by Cardium in 2006. Other potential applications for TRC's Nikola Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. In that regard, filings by Cardium related to Ad5IGF-1 also described the potential
herbal remedies for night fall
use of stem cells, such as mesenchymal stem cells or MSCs transfected with an Ad5IGF-1 vector (such as that used in Corgentin(TM)), for addressing coronary syndromes such as heart disease or heart attack. Cardium also reported that the audit opinion accompanying its consolidated financial statements for the year ended , which statements were included in its Annual Report on Form 10-K filed
herbal plants for fertility
with the Securities
herbal meds
and Exchange Commission in contained a going concern qualification from its independent registered public accounting firm, Marcum & Kliegman LLP. For example, there can be no assurance that results or trends observed in pre-clinical studies will be reproduced in subsequent studies, that human clinical trials can be conducted and completed in an efficient and successful manner, that partnering, asset monetization or other strategic development opportunities can be successfully achieved and that such opportunities will effectively and efficiently advance commercialization of our products, that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain
thyroid natural remedies
our stock
alternative medicine
exchange listing or adequately fund ongoing operations, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study will be reproduced in subsequent studies, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective,
natural remedies
south american natural remedies
easier to use or less expensive.

A complementary approach to the development of therapeutics for regenerative medicine involves the use of stem cells that can be incorporated into injured tissue like the heart as a means of preventing further damage and promoting healing of the affected organ. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier

himalayan herbal medicines
encoding human platelet-derived growth factor-BB (PDGF-BB). InnerCool also developed a new class of targeted organ-specific cooling applications, including its UroCool(TM) pelvic cooling catheter system, which is designed to induce localized cooling during surgery for prostate cancer.

And its subsidiaries, InnerCool Therapies, Inc. With continued clinical advancement, Excellarate offers the potential to be commercially available in late 2011 or peirce 2012. The total shares of com stock outstanding at were

natural healing
46.9 million compared to 41.0 million at. Consistent with Cardium's business strategy, the Company believes that InnerCool has reached a significant valuation inflection point within Cardium's investment portfolio, and with the appropriate strategic positioning, best-in-class products and a pipeline of innovative product opportunities, Cardium intends to advance InnerCool's therapeutic cooling and warming products into corresponding markets through the strategic sale of the business to a large and diversified medical device company or through various vertical partnering opportunities with established companies having existing sales and marketing organizations but with a continuing need for innovative, high-value content products. Non-cash charges relating to stock-based compensation, depreciation and amortization for the year ended totaled $4.0 million compared to $3.5 million in 2007.

Corgentin(TM) (Ad5IGF-1) is designed to enhance myocardial healing in and around the infarct zone when used as an adjunct to existing vascular-directed

herbal products
herbal supplements that is good for esophagus
pharmacologic and interventional therapies - for potential use in treating acute ischemic injury such as that following a heart attack. Cardium ended the year with cash and cash equivalents totaling $1.1 million compared to $7.7 million the previous year. An application for FDA 510(k) clearance of the UroCool(TM) system was submitted in the first quarter of 2009. For the quarter ended , the Company reported a net loss of $5 million, or $(0.11) per share, which included research and development costs totaling $2 million and selling, general and administrative expenses of $2.6 million.
herbal viagra
And the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications.

In Cardium reported that it was focusing principal near-term efforts on its InnerCool Therapies and Tissue Repair subsidiaries - both of which we believe are nearing completion of their strategic development programs initiated in 2006. Actual results may also differ substantially from those described in or contemplated by this due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon

natural health
proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other
retina detachtment herbal treatment
risks described from time to time in filings we make with the Securities and Exchange Commission. Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers.

As a result of Cardium's efforts, InnerCool is now uniquely positioned with a portfolio of temperature modulation therapy products and products under development that include endovascular and surface-based systems (for cooling and warming) that are easy to use and address a wide range of care environments, such as emergency vehicles, emergency rooms and intensive care units, and in operating room settings such as in neurology, cardiac and urology surgeries. For more information about

natural remedies
Cardium's Tissue Repair Company subsidiary, please visit. The decrease in research and development costs was primarily due to a reduction in the development costs for InnerCool's RapidBlue system as it has moved from development to production, increased expenses in our efforts to advance our Excellarate product candidate in its Phase 2b clinical trial, offset by reductions in the AWARE Phase 3 clinical trial costs.

Except for statements of historical fact, the matters discussed in this are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our

herbal products
control and may cause actual results to differ materially from stated expectations. Cardium received notification
natural remedies hypothroidism dogs
in late February that its plan had been accepted by the exchange, but remains subject to continuing review by the exchange with respect to the carrying out of its plan and the achievement and maintenance of overall compliance. TRC's product candidate, Excellarate(TM), is a DNA-based topical gel designed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. In late Cardium received notification from the staff of its current listing exchange indicating that the Company was considered to be noncompliant with certain listing requirements of the NYSE Amex. During 2008, the Company completed three follow-on registered direct investments by institutional and other accredited investors with gross proceeds totaling approximately $11.9 million, and the completion of a secured debt financing resulting in gross proceeds of approximately $6.0 million, before placement agent fees and offering expenses and excluding any future proceeds from the exercise of the warrants issued in the financings. The Company's GAM technology has potential utility in additional indications in which protein therapeutics have had limited success, including the treatment of other dermal wounds (e.g., pressure ulcers) and with orthopedic products, including those for repair of damaged hard tissue (e.g., bone) and soft tissue (e.g., ligament, tendon and cartilage). Biologics and Stem Cells for Cardiovascular Disease and Other Indications Cardium has also developed additional biologics for potential application in cardiovascular disease and other areas of regenerative medicine.

Recent highlights and ongoing product development and clinical research activities

is herbal life good for a diabetic
at InnerCool include the following. The Company believes this strategy is more cost-effective than building InnerCool into a fully integrated manufacturing, sales and marketing organization. This profile would represent a dramatic change from current treatment approaches, which are often not predictably effective and which typically require multiple clinic visits, or in the serge of a protein-based treatment, require daily wound cleanings and product applications over an extended period of time.

With regard to stem cell approaches, recently reported studies conducted by independent researchers at the University of Cincinnati sho in a preclinical model of heart attack that MSCs that had been transfected with Ad5IGF-1 were particularly effective at promoting angiogenesis within the heart and that the zone of heart attack related tissue damage (the infarct zone) was significantly reduced, and cardiac contractile function significantly improved - further highlighting the potential value of these therapeutic approaches. /cgi-bin/prnh/20051018/CARDIUMLOGO) Recent Developments and 2009 Outlook Cardium's business is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address significant unmet medical needs, and definable pathways to commercialization, partnering or other monetization. Cardium's Tissue Repair Company subsidiary (TRC) is focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. Cardium's Generx(R) product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic designed for potential application by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina.